COVID-19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 7, 2020.
Disgraced pharma executive Martin Shkreli is pleading to be temporarily let out of prison in order to join in the fight against COVID-19, the disease that has swept across the globe infecting more than 1.3 million people across the globe.
Following close on the heels of its vaccine development agreement with China’s Xiamen Innovax Biotech, GlaxoSmithKline forged a research and development deal with Vir Biotechnology to develop treatments for COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 6, 2020.
One of the promising experimental drugs being tested to treat COVID-19, the disease caused by the novel coronavirus SARS-Cov2-, is Gilead Sciences’ remdesivir.
SARS was called the first pandemic of the 21st century. It would not be the last. Nor would it be the most deadly.
When tested in mice, the vaccine, which is delivered through a fingertip-sized patch, produced the antibodies specific to the novel coronavirus that causes COVID-19.
Novartis announced that, with Incyte, it is launching a Phase III clinical trial to determine if their cancer drug Jakavi (ruxolitinib) can be used to treat COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 3, 2020.
The U.S. Food and Drug Administration approved the first blood test that looks for the antibodies against the novel coronavirus that causes COVID-19.
PRESS RELEASES